Targets › COL7A1
4 programs from 4 companies in 4 trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Other, Oncology, Immunology; next expected readout Dec 2026.
Stratified squamous epithelial basement membrane protein that forms anchoring fibrils which may contribute to epithelial basement membrane organization and adherence by interacting with extracellular matrix (ECM) proteins such as type IV collagen. (UniProt, Q02388)
Open in Phaseline: the race on COL7A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Krystal Biotech | KB803 Replication-defective, non-integrating HSV-1 expressing human collagen VII protein | COL7A1 | Phase 3 | Dystrophic Epidermolysis Bullosa | Dec 2026 |
| Stanford University | BVEC (Beremagene Geperpavec) COL7A1 gene therapy; induces C7 (type VII collagen) expression | COL7A1 | Phase 2 | Squamous Cell Carcinoma | Feb 2027 |
| CHU de Quebec-Universite Laval | Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB- Retroviral vector-mediated gene therapy delivering COL7A1 to patient-derived keratinocytes | COL7A1 | Phase 1 | RDEB | Dec 2030 |
| Fundación DEBRA Chile, Niños Piel de Cristal | ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops) Amniotic fluid secretome containing extracellular matrix proteins (collagen type VII, lami | COL7A1, LAMA3 | Phase 1 | Junctional Epidermolysis Bullosa | – |
Junctional Epidermolysis Bullosa (1) Dystrophic Epidermolysis Bullosa (1) Squamous Cell Carcinoma (1) RDEB (1)
protein or peptide (3), other (1)
Fundación DEBRA Chile, Niños Piel de Cristal (1) Krystal Biotech (1) Stanford University (1) CHU de Quebec-Universite Laval (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.